Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00016016 · ClinicalTrials.gov registry record · Phase 1
Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Acute Leukemia
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 53
- Enrollment target
NCT00016016: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00016016 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 53 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00016016, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 53 participants
- Enrollment target
Study Summary
Phase II trial to study the effectiveness of combining flavopiridol and cytarabine with mitoxantrone in treating patients who have acute leukemia. Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
Interventions
- OTHER pharmacological study
- DRUG cytarabine
- DRUG alvocidib
- DRUG mitoxantrone hydrochloride
- OTHER laboratory procedure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2001-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00016016
The ClinicalTrials.gov registry entry for NCT00016016 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which pharmacological study is the first listed.
NCT00016016 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00016016 about?
NCT00016016 is a clinical study titled "Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Acute Leukemia". Phase II trial to study the effectiveness of combining flavopiridol and cytarabine with mitoxantrone in treating patients who have acute leukemia. Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill m...
What is the current status of trial NCT00016016?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2001-02.
What interventions are being tested in trial NCT00016016?
The interventions under investigation include: pharmacological study (OTHER), cytarabine (DRUG), alvocidib (DRUG), mitoxantrone hydrochloride (DRUG), laboratory procedure (OTHER).
Who is sponsoring clinical trial NCT00016016?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.